• Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar

Edda Technology

Leading Computer Assisted Radiology & Surgery Solutions

  • Home
  • About EDDA
    • Overview
    • Management Team
    • Careers
  • Products
    • IQQA®-BodyImaging Liver
    • IQQA®-BodyImaging Lung
    • IQQA®-BodyImaging Kidney
    • IQQA®-BodyImaging Interventional
    • IQQA®–Guide
    • IQQA®–Chest
    • IQQA®–Liver
    • IQQA®-Liver Function
    • IQQA®-eQMR
  • News
  • Events
    • Upcoming Events
    • Past Events
  • Contact Us
  • Search
  • Home
  • About EDDA
    • Overview
    • Management Team
    • Careers
  • Products
    • IQQA®-BodyImaging Liver
    • IQQA®-BodyImaging Lung
    • IQQA®-BodyImaging Kidney
    • IQQA®-BodyImaging Interventional
    • IQQA®–Guide
    • IQQA®–Chest
    • IQQA®–Liver
    • IQQA®-Liver Function
    • IQQA®-eQMR
  • News
  • Events
    • Upcoming Events
    • Past Events
  • Contact Us
  • Search
EDDA Technology 3D Imaging Software

Lung CAD Earning a Spot in Day-to-Day Practice

July 1, 2008 //  by Edda Technology

Health Imaging & IT | July 1, 2008 | Special Section: CAD’s Impact on Radiology

By Jonathan Batchelor
Fueled by clinical studies, integration with IT and reimbursement

The integration of computer-aided detection (CAD) software into the day-to-day practice of radiology has witnessed the enthusiastic adoption of the applications for some clinical indications. Mammography CAD, which was first greeted with skepticism and suspicion by radiologists, has since enjoyed a groundswell of support. Lung CAD, thanks to diligent efforts by early adopters, is showing signs that it may be the next area of medicine to embrace widespread utilization of this technology.

According to the American Cancer Society, lung cancer is difficult to treat because it is rarely caught in its earliest stages—when treatment options are most effective. As such, only 16 percent of patients diagnosed with lung cancer have a 50 percent chance of living beyond five years.

Given those statistics, a CAD application that can improve the diagnostic certainty of a primary evaluation for lung cancer and automatically track changes in nodule size during follow-up studies should be warmly welcomed by the clinical community. Although the technology was approved by the FDA in 2001 for chest radiography, and in 2004 for CT, it has not yet achieved the support and infiltration mammography CAD enjoys.

However, an ever-growing bibliography of peer-reviewed scientific journal articles demonstrating its efficacy, the integration of applications into enterprise healthcare systems, and reimbursement for its use by more payors signals that the technology may at last be poised for mainstream adoption.

Radiography CAD Gets Results


A recent prospective study published in Academic Radiology (May 2008) conducted by Edwin J.R. van Beek, MD, PhD, and colleagues in the department of radiology at the Carver College of Medicine, University of Iowa in Iowa City, Iowa, provides strong support for lung CAD utilization.

Chest radiography was performed using a Siemens Medical Solutions DR unit on 324 patients for surveillance of metastatic disease with known malignancy. Their exams were interpreted by experienced pulmonary radiologists via the PACS at the facility, and utilized IQQA®-Chest CAD software from EDDA Technology.

The study evaluated the sensitivity and specificity of the radiologists’ diagnostic interpretations with and without the use of CAD. For studies without the assistance of CAD, the radiologists’ diagnostic performance showed a sensitivity of 63.6 percent and a specificity of 98.1 percent. However, with the addition of CAD, the radiologists demonstrated a specificity of 92.7 percent and a specificity of 96.2 percent.

“This benefit [lung CAD utilization] might have important implications, related to the identification of patients for whom therapy is failing or in the identification of early metastatic disease where different treatment regimens are still available,” the authors wrote. “Both observations should result in important management decisions, thus improving overall patient care.”

Category: Press Release

Previous Post: « EDDA Participates in ILC 2008
Next Post: EDDA Technology Launches IQQA®-Liver New Release for Fast Volumetry Assessment from Liver MDCT »

Primary Sidebar

Contact Us

609-919-9889
5 Independence Way, Princeton, NJ 08540

Request A Demo »

Explore Our Products

  • Overview
  • IQQA®-BodyImaging Liver
  • IQQA®-BodyImaging Lung
  • IQQA®-BodyImaging Kidney
  • IQQA®-BodyImaging Interventional
  • IQQA®-Guide
  • IQQA®-Chest
  • IQQA®-Liver
  • IQQA®-Liver Function
  • IQQA®-eQMR

Resources

  • Talks & Publications
  • Press & Media 2011 – Present
  • Press & Media 2004 – 2010
  • Training & Tutorials for Existing Clients
  • Download Manuals

Search this Website

EDDA-Technology-Logo
Frost & Sullivan Applauds EDDA's IQQA® Platform, an Advanced Imaging Analytics Technology that Improves Clinical Workflow and Accuracy

609-919-9889

5 Independence Way, Princeton, NJ 08540

Additional Resources

  • Talks & Publications
  • Press & Media 2011 – Present
  • Press & Media 2004 – 2010
  • Training & Tutorials for Existing Clients
  • Download Manuals

Explore Our Products

  • liver-icon

    IQQA® BodyImaging Liver

  • lung-icon

    IQQA® BodyImaging Lung

  • kidney-icon

    IQQA® BodyImaging Kidney

Copyright © 2003 – 2025 EDDA Technology, Inc. All rights are reserved. | Site Map